Polatuzumab Vedotin Boosts Survival in Relapsed DLBCL
8h agoen
From the article
Patients with relapsed or refractory diffuse large B-cell lymphoma, who were ineligible for autologous stem cell transplant, were randomly assigned to receive Pola-R-GemOx or R-GemOx. Medscape Medical News
Continue reading on MedscapeYou might also wanna read
A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia
clinicaltrials.gov·17h ago
Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)
clinicaltrials.gov·7d ago
Reassessment of the Risk of Hemolytic Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With a Regimen Containing Venetoclax
clinicaltrials.gov·1d ago
Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy
clinicaltrials.gov·3d ago
Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma
clinicaltrials.gov·8d ago
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
clinicaltrials.gov·8d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.